摘要
Abstract
Objective To study the clinical efficiency, safety, the survival, and life quality of oxaliplatin combined with thymosin pleu-ral perfusion for treatment of patients with lung cancer accompany with malignant pleural effusion. Methods 120 patients with lung cancer accompany with malignant pleural effusion are selected for forward-looking study in our hospital from June 2015 to June 2016. They are divided into control group and study group at random, 60 cases for each group. Patients in control group are treated with intrapleural infu-sion of oxaliplatin, and patients in study group are given intrapleural infusion of oxaliplatin combined with thymosin. Short-term therapeutic efficacy, the clinical benefit, toxic reaction occurred, immunity, inflammation improvement and survival are evaluated. Results The RR rate and CBR rate of patients in the study group were 88.33% and 80.00% which was significantly higher than those in the control group (66.67% and 61.67%) (P<0.05); the incidence of toxic and side effects in the study group was significantly lower than that in the control group (21.67% vs. 68.33%, P<0.05), the degree of toxic and side effects of patients in the two groups were Ⅰ~Ⅱ grade, which were improved after symp-tomatic treatment; The CD4+, CD8+ and CD3+ levels of patients in the study group were significantly higher than those in the control group (P<0.05), and TNF-α and IL-6 were significantly lower than those in the control group (P<0.05); the survival rate of 4~6, 7~9 and 10~12 months of patients in the study group was significantly higher than that in control group (P<0.05). Conclusion Oxaliplatin combined with thymosin pleural perfusion has remarkable effect for treatment of lung cancer accompany with malignant pleural effusion, the incidence rate of adverse reaction is low and slight, prolongs survival time of patients, and improves their quality of life.关键词
肺癌/恶性胸腔积液/奥沙利铂/胸腺肽/胸腔灌注/疗效/安全性Key words
Lung cancer/Malignant pleural effusion/Oxaliplatin/Thymosin/Pleural perfusion/Efficacy/Safety分类
医药卫生
